Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Antibody plus paclitaxel improves survival in patients with metastatic disease
May 5th, 2005
Genentech, Inc. (DNA) and Roche (SWX Zurich) announced that an interim analysis of a Phase III study of Avastin (bevacizumab) plus paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of showing an improvement in progression-free survival, compared to chemotherapy alone. "This study is very important for two reasons: it demonstrates that Avastin has clinical benefit when used in combination with chemotherapy in first-line metastatic breast cancer and reinforces our belief that targeting angiogenesis can result in patient benefit in multiple tumor types, including colorectal and nonsmall cell lung cancers," said Hal Barron, MD,...
Source: Women's Health Weekly (2005-05-05)
|
